Neurocrine Biosciences Inc (NBIX)

Investment Committee Summary

Investment Thesis

Neurocrine Biosciences develops and sells prescription medicines for neurological, endocrine and psychiatric disorders, largely in the United States. It is a commercial-stage biopharma: a concentrated marketed portfolio funds a research and launch pipeline, and the engine models an operating margin near 26% with net debt of ~$0.1B — effectively an unlevered balance sheet. At $155 on 9 September 2026 the shares are fairly valued against the engine's triangulated fair value (+1%), at roughly 22 times forward earnings. That multiple is neither a growth multiple nor a run-off multiple; it is the market splitting the difference between the base case, in which the pipeline offsets loss of exclusivity, and the structural case, in which it does not. The variable that decides the outcome is pipeline timing against the patent clock — whether new launches and indication expansions reach commercial scale before exclusivity on the current revenue base erodes. The most damaging risk is that this is a binary the multiple cannot express: one late-stage failure or an adverse pricing determination removes the offset entirely, and the earnings base becomes a declining annuity rather than a growing one.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($155) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The bear case does not require a demand shock. Concentrated biopharma revenue erodes on a schedule: when exclusivity lapses, generic or biosimilar entry takes the majority of unit volume within quarters rather than years, and price falls with it. Government drug-pricing negotiation compresses the same base from the other side, ahead of patent expiry. Against that, the pipeline is the only offset, and pipeline outcomes are not smooth — a failed readout or a delayed approval does not cost a quarter of growth, it removes an entire replacement revenue stream. In that state the modelled operating margin near 26% falls faster than revenue, because commercial and research infrastructure was scaled for the launch that did not happen. A multiple of roughly 22 times forward earnings on a shrinking base then de-rates towards a run-off valuation, which is why the engine's structural branch prices below the 52-week low. The clean balance sheet buys time; it does not create a replacement molecule.

Key Debate

P/E Multiple explains 71% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

What the Market Is Pricing In

At the current price, the market pays 15.2× consensus forward EPS, vs the house DCF terminal 20.0×, and a peer median 14.8×. The house DCF sits 6% below spot, so the market is pricing in more than the house case — roughly 0.8pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily FCF-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Patent Cliff (LOE) / IRA Pricing Erosion' downside ($75.82) to a 'Bull — Blockbuster / Pipeline Re-Rate' bull case ($305); the probability-weighted blend (PWEV $172) is +11% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — stock-based compensation runs at 7.0% of revenue; free cash flow net of SBC is $0.53B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Patent Cliff (LOE) / IRA Pricing Erosion (20%, $75.82). Structural impairment — patent cliff (LOE) / IRA pricing erosion: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Pipeline Setback / Pricing Pressure (17%, $129). Cyclical downturn — drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory weakens for 1–2 years before normalising.
• Base — Pipeline Offsets LOE (35%, $179). Mid-cycle — normalised drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory; disciplined capital allocation; steady returns.
• Growth — Launch / Indication Expansion (20%, $241). Upside — pipeline launches + indication expansion lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Blockbuster / Pipeline Re-Rate (8%, $305). Upside tail — sustained tight conditions or a structural re-rate on pipeline launches + indication expansion.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $155 and 50% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (71% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 20.0x terminal FCF multiple → $145. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $184; the peer-median forward P/E is 14.8x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 23% of the median — moderate (healthy method disagreement — read the blend with care).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Biopharma multiple (AI re-rating) (base 24.0x)

Peer Quality & Weighting

Quality-weighted forward P/E: 16.2× (simple median 14.8×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $122–$186, centre $150 (-3% vs spot); spot sits at the 52nd percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; here the modelled upside is under a twentieth of the modelled downside, so the displayed ratio would read as exactly zero and is withheld rather than printed as a figure the document would immediately disown. Bull case (Bull — Blockbuster / Pipeline Re-Rate): $305.

Company Overview & Business Model

Neurocrine Biosciences Inc — HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC. Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.

How it makes money.

Edge. Wide moat — inferred from a 26% operating margin and the biopharma business model. Durable pricing power supports a terminal multiple above the market.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Care — Pharma

This name sits in the Health Care — Pharma cluster as a biopharma name. drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory. Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: UTHR (biopharma) · NBIX (biopharma) · JAZZ (biopharma) · EXEL (biopharma) · ELAN (biopharma) · BMRN (biopharma) · CYTK (biopharma) · ARWR (biopharma) · HALO (biopharma) · RGEN (biopharma)

Mapping note: name-level 'Structural — Patent Cliff (LOE) / IRA Pricing Erosion' (20%) + 'Pipeline Setback / Pricing Pressure' (17%) map to cluster Patent Cliff / IRA Pricing Erosion (37%); name-level 'Growth — Launch / Indication Expansion' (20%) + 'Bull — Blockbuster / Pipeline Re-Rate' (8%) map to cluster Upside — Launches / Pipeline Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Patent Cliff / IRA Pricing Erosion — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The Health Care — Pharma cycle is the shared macro driver. Driver — drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory. Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 164% — cash-backed.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.40 vs analyst floor +0.00 → delta +0.40 (n=41 mgmt / 23 Q&A; 49th pctile across the S&P book, z -0.1).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 543 articles): avg ticker sentiment +0.22 (bullish 32% / bearish 2%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-10-27 (~49d) — Quarterly earnings — est. EPS $1.99 (AV EARNINGS_CALENDAR)

Forecast Track Record

• EPS surprise: beat 50% of the last 8 quarters; average surprise -1.6%.
• Prior-forecast backtest (19 snapshots, 2026-07-21→2026-09-03): directional hit-rate 63%; mean predicted +7.3% vs realised -3.4%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

5 catalysts in the next 90 days (of 13 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 0 bearish / 0 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic revenue growth / order backlog < flat-to-negative for two consecutive quarters (2 consecutive prints). Sustained demand rollover breaks the base case toward the recession scenario.
• FY revenue ($B) < 3.15 (next reported fiscal year). (rationale withheld pending re-authoring — frozen figure or verdict)
• Probability-weighted fair value (PWEV) at the next re-run < 155.13 (any scheduled re-run). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $155; 52-week range $122–$186; engine rating HOLD; house target $172 (+11%). (source: Alpha Vantage 2026-09-08, 9 September 2026)
• INFERENCE: Triangulated FV $156 (+1% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

68.5/100 (confidence band 60.3–76.7), 88th percentile of 893 covered names (as of 2026-09-08). Weighted composite under config ros-1.20.0 — every component and its inputs below.

Score history: 67.7 → 67.8 → 67.9 → 67.5 → 68.7 → 68.6 → 68.9 → 68.4.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $172.32.

Factor Exposures

Cross-sectional percentiles over 893 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.31, vs QQQ +0.27 (trailing ~1y daily returns).

Options Intelligence

Preferred structure: Long Stock. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• no directional edge and options are cheap — options add little; hold the stock
• Direction neutral from the overlay conviction/rating (read-only input).
• IV/RV at the 11th percentile of the cross-section → low vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 33rd percentile of its own month-end history (decile 4). The two measures disagree here — vol is high for this name by its own history while its options are not unusually rich against its realised vol. Where they diverge, the cross-sectional measure is the one acting.
• IV term structure is in contango (longer-dated richer, slope +11.7pp) — favour longer-dated ownership (LEAPS) or calendars that are long the cheaper front.
• No live-chain Long Stock was priced for this name — shown as the indicated strategy; size against a freshly pulled chain.

IV term structure (contango, slope +11.7pp): 38-DTE 29% · 101-DTE 36% · 311-DTE 40%

No live-chain Long Stock was priced for this name — shown as the indicated approach; size against a fresh chain.

Alternatives: . IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the HOLD equity view. Chain as of 2026-09-08 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 28.8% (subdued regime) · expected move ±7.4% (2026-10-16) · put/call OI 0.71 · ATM Δ 0.54 / Θ -0.09 / ν 0.20 · next earnings 2026-10-27. Direction: NEUTRAL (implied return +0.8% to triangulated fair value $156.34).

Covered Call (if held) (Income / neutral) — Short 165 C · 2026-10-16 · premium $2.35 · yield 1.5% · priced from the listed chain (EOD marks)

Converts a near-fair holding into income by agreeing to sell at a higher strike — worth weighing when upside looks limited near fair value and being called away is acceptable. Illustrative — no outcome is implied or guaranteed.

Put Spread (income) (Income / would-own) — Short 145 P / Long 130 P · 2026-10-16 · net $1.69 · net entry $143.31 · yield 1.2% · RoR 13.0% · max loss $13.31 · priced from the listed chain (EOD marks)

Gets paid to wait for a lower entry, with the tail capped: the sold put collects premium while the cheaper long wing below it caps the maximum loss at the spread width — a defined-risk alternative to a naked cash-secured put.

Protective Collar (if held) (Hedge) — Long 140 P / Short 170 C · 2027-03-19 · net $4.95 · floor -10.0% · cap +10.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies +11% vs spot
• Monte Carlo median implies +0% vs spot
• DCF fair value implies -6% vs spot
• Bear case (Structural — Patent Cliff (LOE) / IRA Pricing Erosion) downside is -51% vs spot
• Net: a reward leg exists but is negligible against the bear case — the reward-to-risk ratio would round to zero at display precision, and a displayed zero asserts a reward leg that is effectively absent — so the ratio is withheld as not asymmetric enough to print. The rating is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 6% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $3B + PV(terminal) $11B = EV $15B; − net debt $0.1B → equity $14B ÷ diluted shares $0.10B = $145/share (exit-multiple terminal).

• Gordon terminal at 2.5% → $129/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 14% vs WACC 8.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: EV/Rev → $184 (no P/E-implied price — no forward-EPS basis at the peer step).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Terminal × ±15% (35.0); Revenue CAGR ±3pp (35.0); Op margin ±3pp (32.0); WACC ±1pp (12.0); Capex intensity ±15% (11.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 20×, FY+5 revenue $4B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.